Who owns Design Therapeutics, Inc. (DSGN)? Elite investor 13F holders
2 tracked elite investors reported holding Design Therapeutics, Inc as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | DESIGN THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 5613101.00 USD | 387913.000000 | Shares | reduce | Original filing |
| D.E. Shaw | DESIGN THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 2830983.00 USD | 195645.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.